0
Clinical Investigations: PULMONARY VASCULATURE |

Primary Pulmonary Hypertension In Israel*: A National Survey

Liat Appelbaum, MD; Mordechai Yigla, MD; Daniell Bendayan, MD; Nira Reichart, MD; Gershon Fink, MD; Israel Priel, MD, FCCP; Yehuda Schwartz, MD; Paul Richman, MD, FCCP; Eli Picard, MD; Silvia Goldman, MD; Mordechai R. Kramer, MD, FCCP
Author and Funding Information

*From the Pulmonary Institute (Dr. Appelbaum), Hadassah University Medical Center, Jerusalem, Israel; the Pulmonary Institute (Dr. Yigla), Rambam Medical Center, Haifa, Israel; the Pulmonary Institute (Dr. Reichart), Shiba Medical Center, Tel-Hashomer, Israel; the Pulmonary Institute (Drs. Kramer, Fink, and Bendayan), Rabin Medical Center, Petah-Tikvah, Israel; the Pulmonary Institute (Dr. Priel), Pulmonary Department, Wolfson Medical Center, Holon, Israel; the Pulmonary Institute (Dr. Schwartz), Ichilov Medical Center, Tel-Aviv, Israel; Haemek Medical Center (Dr. Richman), Afula, Israel; the Pulmonary Institute (Dr. Picard), Shaarey-zedek Medical Center, Jerusalem, Israel; the Epidemiology Department (Dr. Goldman), Hadassah University Medical Center, Jerusalem, Israel.

Correspondence to: Mordechai R. Kramer, MD, FCCP, Institute of Pulmonology, Rabin Medical Center, Petach Tikva, 49100 Israel; e-mail: pulm@netvision.net.il



Chest. 2001;119(6):1801-1806. doi:10.1378/chest.119.6.1801
Text Size: A A A
Published online

Objectives: To characterize the incidence of patients with primary pulmonary hypertension (PPH) in Israel and their outcomes.

Methods: We have evaluated retrospectively all the patients in Israel in whom PPH was diagnosed between the years 1988 and 1997. We looked at medical history, hemodynamic data, pulmonary function and gas exchange, and demographic variables. Patients were followed up for survival until November 1997. Life table analysis and Kaplan-Meier statistics were used to estimate the overall survival distribution. Regression analysis was used to examine the relations between survival and selected variables.

Results: Overall, we found 44 patients with PPH. The estimated incidence of PPH in Israel is 1.4 new cases per year per million population. The mean (± SD) age at diagnosis was 43 ± 13 years. In the Jewish population, PPH was more frequent among immigrants from Europe and the United States. The mean interval from the onset of symptoms to diagnosis was 3 years (median, 2 years). The median survival time was 4 years. The 1-year, 3-year, and 5-year survival rates were 82%, 57%, and 43%, respectively. The major variables influencing the survival rate were the following: interval from symptom onset to diagnosis; and hemodynamic measurements (ie, mean pulmonary artery pressure, mean right atrial pressure, and cardiac index). In comparison to rates discerned from the National Institutes of Health registry data, the survival rate in Israel is somewhat better and prognosis is influenced by similar hemodynamic variables.

Conclusion: PPH is a rare and fatal disease in Israel. New therapeutic modalities such as prostacyclin therapy and lung transplantation may improve survival among patients with this malignant disease.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543